Shanghai Finetech pharm Co., ltd.

F-001 is a novel microtubule inhibitor, known as "oral paclitaxel drug." Efficacy than paclitaxel is good, and has a small side effects, oral bioavailability of high characteristics. Is a small molecule tubulin inhibitor (mitotic inhibitor), the main purpose is to treat cancer. SA001 has a very high anti-cancer activity, the efficacy of similar drugs have been listed such as paclitaxel (paclitaxel) and vinblastine (Vinblastine) and so on or better, but SA001 has a simple structure, easy production, excellent water solubility, good oral absorption advantage. SA001 has completed preclinical studies of prostate cancer in the United States, including synthetic process optimization / pilot, pharmacokinetics, pharmacology (animal experiments), drug safety assessment (toxicology), and now in the preparation of clinical I / II test.

Compared to the market of similar drugs, F-001 has the following main advantages:

1) first-in-class tubulin inhibitors that can be administered orally;

2) simple structure, low production cost, excellent water solubility, good oral absorption;

3) Anticancer effect is comparable to paclitaxel and is effective against paclitaxel resistance (drug resistance) in cancer and androgen-resistant prostate cancer.

All of the tubulin inhibitors currently on the market are natural products or semi-synthetic natural products, complex structure, high extraction / production costs. In addition, water solubility and poor oral absorption, it must be added to the solvent solution, must be injected by injection, greatly increasing the cost of medication and solvent-related side effects, such as paclitaxel (paclitaxel) and vinblastine (Vinblastine) and so on. So as the first can be oral administration of tubulin inhibitor SA001 will have unparalleled advantages: high efficiency, fewer side effects, more convenient for patients with medication.